Completed PHASE1 INTERVENTIONAL 4-arm NCT02096614

Investigator Initiated Phase 1 Study of TBI-1201

Multi-center, Investigator Initiated Phase 1 Study of MAGE-A4 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors

Sponsor: Fiverings Co., Ltd.

Conditions Solid Tumors

Interventions Cyclophosphamide Fludarabine TBI-1201

Updated 7 times since 2017 Last updated: Jun 13, 2021 Started: Apr 30, 2014 Primary completion: Mar 31, 2021 Completion: Mar 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Tumors, this trial is completed. The trial is conducted by Fiverings Co., Ltd. and has accumulated 7 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jan 2021 — Sep 2021 [monthly]

Unknown Status PHASE1
Dec 2019 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Dec 2019 [monthly]

Recruiting PHASE1
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fiverings Co., Ltd.
Mie University
Shionogi
Statcom Co. Ltd.
Takara Bio Inc.

Data source: Mie University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tsu, Japan